Researchers at Chinese Academy of Science Have Reported New Data on Breast Cancer [Co-delivery of doxorubicin and RNA using pH-sensitive poly (beta-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer]
By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "An appropriate co-delivery system for chemotherapeutic agents and nucleic acid drugs will provide a more efficacious approach for the treatment of breast cancer by reversing multidrug resistance (MDR). In this work, a new amphiphilic poly (beta-amino ester), poly[(1,4-butanediol)-diacrylate-beta-5-polyethylenimine]-block-poly[(1,4-butanediol)-diacrylate-beta-5-hydroxy amylamine] (PDP-PDHA) was synthesized, and the doxorubicin (DOX) and survivin-targeting shRNA (shSur) co-loading nanoparticle (PDNs) were prepared."
Our news journalists obtained a quote from the research from the Chinese Academy of Science, "The pH-sensitive poly[(1,4-butanediol) diacrylate-beta-5-hydroxy amylamine] (PDHA) endowed PDNs both pH-triggered drug release characteristics and enhanced endo/lysosomal escape ability, thus improving the cytotoxicity of DOX and the transfection efficiency. PDNs also increased the DOX accumulation, down-regulated 57.7% survivin expression, induced 80.8% cell apoptosis and changed the cell cycle in MCF-7/ADR cells. In the MCF-7/ADR tumor-bearing mice models, after administrated intravenously, PDNs raised the accumulation of DOX and shSur in the tumor tissue by 10.4 and 20.2 folds, respectively, resulting in obvious inhibition of the tumor growth with tumor inhibiting rate of 95.9%. The combination of DOX and RNA interference showed synergistic effect on overcoming MDR."
According to the news editors, the research concluded: "Therefore, PDNs could be a promising co-delivery vector for effective therapy of drug resistant breast cancer."
For more information on this research see: Co-delivery of doxorubicin and RNA using pH-sensitive poly (beta-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. Biomaterials, 2014;35(23):6047-6059. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
The news correspondents report that additional information may be obtained from S. Tang, Chinese Academy Sci, Shanghai Inst Mat Medico, Shanghai 201203, People's Republic of China. Additional authors for this research include Q. Yin, Z.W. Zhang, W.W. Gu, L.L.L. Chen, H.J. Yu, Y.Z. Huang, X.Z. Chen, M.H. Xu and Y.P. Li (see also Oncology).
Keywords for this news article include: Asia, Antibiotics - Antineoplastics, Pharmaceuticals, Drugs, Therapy, Shanghai, Oncology, Nanoparticle, Breast Cancer, Nanotechnology, Women's Health, Emerging Technologies, Doxorubicin Hydrochloride, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC